MINA Antibody
| Code | Size | Price |
|---|
| PSI-5617-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-5617-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
MINA Antibody: ROX, MDIG, NO52, MINA53, Bifunctional lysine-specific demethylase and histidyl-hydroxylase MINA, 60S ribosomal protein L27a histidine hydroxylase, ROX
Application Note:
MINA antibody can be used for detection of MINA by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Background:
MINA Antibody: MINA is nuclear localized, myc-inducible protein that is thought to play a role in mammalian cell proliferation. Treatment of cancer cells lines such as the colon cancer cell line SW680 with siRNA against MINA inhibits cell growth, demonstrating that MINA may be a potential therapeutic target. MINA regulates several genes related to cell adhesion and metabolism that have also been shown to be regulated by c-Myc, but also regulates other genes whose expression are not modulated by c-Myc such as EGFR, IL-6 and HGF. MINA has also been found to act as a repressor to IL-4 expression in T cells, indicating that it may also play a role in T cell differentiation and genetic variation in T helper type 2 bias.
Background References:
- Tsuneoka M, Kody Y, Soejima M, et al. A novel myc target gene, mina53, that is involved in cell proliferation. J. Biol. Chem.2002; 277:35450-9.
- Teye K, Tsuneoka M, Arima N, et al. Increased expression of a Myc target gene Mina53 in human colon cancer. Am. J. Pathol.2004; 164:205-16.
- Komiya K, Sueoka-Aragane N, Sato A, et al. Mina53, a novel c-Myc target gene, is frequently expressed in lung cancers and exerts oncogenic property in NIH/3T3 cells. J. Cancer Res. Clin. Oncol.2010; 136:465-73.
- Okamoto M, Van Stry M, Chung L, et al. Mina, an IL4 repressor, controls T helper type 2 bias. Nat. Immunol.2009; 10:872-9.
Buffer:
MINA Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Bovine: (80%), Rat: (80%)
Immunogen:
MINA antibody was raised against a 15 amino acid synthetic peptide near the amino terminus of human MINA.
The immunogen is located within amino acids 380 - 430 of MINA.
The immunogen is located within amino acids 380 - 430 of MINA.
NCBI Gene ID #:
84864
NCBI Official Name:
MYC induced nuclear antigen
NCBI Official Symbol:
MINA
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_694822
Protein GI Number:
110227621
Purification:
MINA Antibody is affinity chromatography purified via peptide column.
Research Area:
Cancer,Cell Cycle
Swissprot #:
Q8IUF8
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | MINA Peptide | PSI-5617P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|